The role of blinatumomab in ALL

The role of blinatumomab in ALL

VJHemOnc

3 years
806 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Philippe Rousselot, MD, PhD from Versailles Hospital and University, Versailles, France, discusses the use of blinatumomab in patients with acute lymphoblastic leukemia (ALL). blinatumomab is a class of bi-specific T-cell engagers (BiTEs) that works by targeting CD19 and CD3 antigens on B-cells. The drug works by bringing the T-cell to the blast and directly promoting lysis. Prof. Rousselot mentions that the toxicity profile is different to other drugs, for example there are no problems associated with the liver or the platelets. Toxicity for blinatumomab is more neurologically based, during the initial phases of the treatment and after the initial phases, it is considered to be a well-tolerated drug. Prof. Rousselot provides an overview of the recent TOWER study (NCT02013167) of blinatumomab and its potential in the treatment of relapsed/refractory ALL. He notes that results show remission rate increased by half, with a very good molecular response rate. However, survival is quite short, but it is better than with chemotherapy. Prof. Rousellot concludes by expressing the importance of thinking about combinations to use those antibodies. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Up Next Autoplay
GRACE Supportive Care Series:   Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
0 Views
cancergrace 1 day
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
0 Views
Cancer-News 2 days
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 2 days
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 2 days
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 2 days
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
Category: Brain Cancer
4 Views
Massachusetts General Hospital 2 days